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AbsTrACT
background and objectives There is a need for local 
anesthetics that provide consistent analgesia through 
72 hours after surgery. This study evaluates the use of 
HTX-011 (bupivacaine and meloxicam in Biochronomer 
polymer technology), an extended-release, dual-acting 
local anesthetic, in reducing both postoperative pain 
over 72 hours and postoperative opioid use when 
compared with bupivacaine hydrochloride (HCl) and 
saline placebo. Inclusion of low-dose meloxicam in HTX-
011 is designed to reduce local inflammation caused by 
surgery, potentiating the analgesic effect of bupivacaine. 
Previously, significant synergy has been observed with 
bupivacaine and meloxicam with both given locally 
together.
Methods EPOCH 1 was a randomized, double-
blind, placebo-controlled and active-controlled phase 
III study in subjects undergoing a primary unilateral, 
distal, first metatarsal bunionectomy in which subjects 
received either a single intraoperative dose of HTX-011, 
immediate-release bupivacaine HCl or saline placebo.
results A total of 412 subjects were dosed. The 
results for the primary and all four key secondary 
endpoints were statistically significant in favor of 
HTX-011. HTX-011 demonstrated superior, sustained 
pain reduction through 72 hours, significantly reduced 
opioid consumption and resulted in significantly more 
opioid-free subjects compared with saline placebo and 
bupivacaine HCl. Safety was similar across groups with 
fewer opioid-related adverse events observed in the HTX-
011 group.
Conclusions HTX-011 demonstrated significant 
reduction in postoperative pain through 72 hours 
with significant reduction in opioid consumption and 
a significant increase in the proportion of opioid-free 
subjects compared with saline placebo and the most 
widely used local anesthetic, bupivacaine HCl.
Trial registration number NCT03295721.
InTrOduCTIOn
More than 500 000 bunionectomy procedures are 
performed in the USA annually, making it one of 
the most common surgeries. Patients most often 
experience the greatest degree of pain within the 
first 72 hours after surgery, with the majority 
experiencing moderate to severe pain.1–5 Periop-
erative administration of local anesthetics such as 
bupivacaine is commonly used in clinical practice 
for managing postoperative pain; however, these 
agents have shown limited efficacy beyond 6–12 
hours, necessitating the use of additional postop-
erative analgesics, including opioids.6–8 Extend-
ed-release liposomal bupivacaine can potentially 
extend the period of pain relief but rarely beyond 
24 hours; it has not shown superiority to bupiv-
acaine hydrochloride (HCl) in bunionectomy.6–8 
There is a need for local anesthetics that can 
provide consistent analgesia through the first 72 
hours when patients experience the most severe 
pain. Opioids are commonly used for postop-
erative pain management. The use of opioids is 
associated with an increased risk of adverse drug 
effects including respiratory depression, seda-
tion, and postoperative nausea and vomiting.9 10 
Across surgical models, poorly managed pain and 
opioid-related adverse events (ORAEs) have been 
shown to contribute directly to patient discomfort, 
dissatisfaction, delayed recovery from surgery, 
increased length of hospital stay and increased 
medical costs.11–14
HTX-011 is a novel, extended-release, dual-
acting local anesthetic that is a fixed-dose combi-
nation of two active ingredients, bupivacaine and 
low-dose meloxicam, incorporated in a proprietary 
Biochronomer polymer. The product is a viscous 
solution administered directly into the surgical 
incision via a syringe with a Luer lock applicator 
to coat the affected tissue prior to suturing. After 
single-dose administration, the polymer enables 
extended release of bupivacaine and meloxicam 
simultaneously over approximately 3 days. Inclu-
sion of low-dose meloxicam in HTX-011 reduces 
local inflammation caused by surgery and normal-
izes the local pH,15 16 allowing the analgesic effect 
of bupivacaine. This synergistic relationship has 
been demonstrated in prior phase II studies in 
bunionectomy and herniorrhaphy, where HTX-011 
led to a substantially greater reduction in pain 
intensity when compared with the same polymer 
formulation containing either bupivacaine alone or 
meloxicam alone.17
The objectives of this randomized, double-blinded, 
placebo-controlled and active-controlled phase III 
study (EPOCH 1) were to evaluate the analgesic 
efficacy and safety of HTX-011 at a single dose of 
60 mg/1.8 mg applied into the surgical site without 
a needle, compared with bupivacaine HCl injection 
(the most widely used local anesthetic for addressing 
postoperative analgesia) and saline placebo in subjects 
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undergoing a primary unilateral, distal, first metatarsal bunionec-
tomy with osteotomy and internal fixation.
MeThOds
study design
The study was conducted at 13 sites across the USA from October 
2017 to March 2018. All subjects provided written informed 
consent prior to participation in any study-specific procedures.
Eligible subjects were required to be at least 18 years of age 
with an American Society of Anesthesiologists physical status of I, 
II or III. The study excluded subjects with a pre-existing, concur-
rent acute or chronic painful physical/restrictive condition that 
could confound the postoperative assessments. Other key exclu-
sion criteria included the use of non-steroidal anti-inflammatory 
drugs (NSAIDs; including meloxicam) within 10 days prior to 
the scheduled surgery, known or suspected daily use of opioids 
for seven or more consecutive days within 6 months prior to 
surgery, long-acting opioids within 3 days prior to surgery, the 
use of any opioids within 24 hours prior to surgery, the admin-
istration of bupivacaine within 5 days prior to surgery and the 
use of systemic steroids within five half-lives or 10 days prior to 
administration of study drug.
Given the double-blind study design, neither the subjects nor the 
investigators involved in conducting postsurgical assessments knew 
which treatment was given. Subjects were randomly assigned using 
a centralized computer-generated blocked randomization algo-
rithm in a 3:3:2 ratio to three treatment groups: (A) HTX-011, 
60 mg/1.8 mg (bupivacaine/meloxicam), 2.1 mL, applied into the 
surgical site without a needle; (B) bupivacaine HCl 0.5%, 50 mg 
(10 mL), via injection into the surgical site; and (C) saline placebo, 
2.1 mL, applied into the surgical site without a needle. On day 1, 
the day of surgery, subjects underwent a unilateral simple Austin-
type bunionectomy under regional anesthesia with no more than 
20 mL of 1% lidocaine without epinephrine administered as 
a Mayo block. Epidural or spinal anesthesia was not permitted. 
During surgery, the use of opioids (other than intravenous fentanyl) 
or other analgesics was prohibited.
Near the end of surgery, after irrigation and suction, a single 
dose of study drug (HTX-011, bupivacaine HCl or saline placebo) 
was administered intraoperatively via local application into the 
surgical site by the investigator. Subjects remained in the hospital/
research facility for a minimum of 72 hours following surgery 
to undergo postoperative assessments including pain intensity, 
opioid use and collection of blood samples for assessment of 
pharmacokinetics. Subjects could only receive rescue medication 
on request to treat postoperative pain, not for pain prophylaxis, 
during the 72 hours postoperative observation period. Postoper-
ative rescue medication consisted of intravenous morphine (no 
more than 10 mg within a 2-hour period as needed), oral oxyco-
done (no more than 10 mg within a 4-hour period as needed) 
and/or oral acetaminophen (no more than 1000 mg in a 6-hour 
window). No other analgesic agents were permitted. After the 72 
hours, assessments were completed, subjects could be discharged 
and were instructed to return to the study site on day 10, day 28 
and day 42 to complete follow-up assessments. After discharge 
through day 28, subjects were to complete a daily diary to record 
whether they took opioids.
Outcome measures
The primary efficacy endpoint was mean area under the curve 
(AUC) of the Numeric Rating Scale (NRS) of pain intensity 
scores through 72 hours (AUC0-72) for HTX-011 compared with 
saline placebo. During the first 72 hours following surgery, the 
NRS was measured at hours 1, 2, 4, 8, 12, 24, 36, 48, 60 and 72. 
Four key secondary efficacy endpoints were: (1) mean AUC0-72 
of the NRS pain intensity scores for HTX-011 compared with 
bupivacaine HCl, (2) mean total postoperative opioid consump-
tion (in morphine milligram equivalents) through 72 hours for 
HTX-011 compared with saline placebo, (3) the proportion of 
subjects who were opioid free through 72 hours for HTX-011 
compared with bupivacaine HCl and (4) the mean total postop-
erative opioid consumption (in morphine equivalents) through 
72 hours for HTX-011 compared with bupivacaine HCl. To 
account for multiple hypothesis testing on the primary endpoint 
and on each of the four key secondary endpoints, a strict testing 
hierarchy was applied to control study-wise alpha level at 0.05. 
Other secondary efficacy endpoints included the proportion of 
subjects with severe pain (defined as an NRS pain intensity score 
≥7 at any timepoint through 72 hours) and the proportion of 
subjects who were opioid free through 72 hours compared with 
placebo, through day 10 and through day 28.
Safety endpoints included the incidence of treatment-emergent 
adverse events (TEAEs), change from baseline in clinical labora-
tory results, ECG, vital signs, wound healing at 72 hours and 10, 
28 and 42 days after treatment, bone-healing X-ray assessments at 
28 and 42 days after treatment and ORAEs. ORAEs were based 
on prespecified preferred adverse event (AE) terms of nausea, 
vomiting, constipation, pruritus, pruritus generalized, somnolence, 
respiratory depression and urinary retention, regardless of whether 
a subject actually received an opioid medication.
statistical analysis
Based on prior phase II studies of HTX-011 in subjects under-
going unilateral simple bunionectomy, a sample size of approxi-
mately 400 subjects (150, 150 and 100 in HTX-011, bupivacaine 
HCl and saline placebo groups, respectively) was needed to 
provide at least 90% power to detect a statistically significant 
difference between the HTX-011 group and the control groups 
for each of the primary and key secondary endpoints.
The primary and first key secondary endpoints were analyzed 
using analysis of variance with treatment group as the main 
effect, together with pairwise t tests to analyze differences 
between treatment groups. Missing data, which were expected 
to be very low due to the 72 hours hospitalization following 
surgery, were imputed via last observation carried forward for 
interval censored pain intensity scores and worst observation 
carried forward (WOCF) for right-censored pain intensity scores 
in the intent-to-treat (ITT) population. To adjust for the anal-
gesic effect of opioid rescue medication, the windowed WOCF 
method was implemented as the primary analysis method 
in which pain intensity scores observed during the analgesic 
window of any opioid rescue medication were replaced with the 
worst postdose, non-missing NRS pain intensity score observed 
prior to the rescue medication window. A sensitivity analysis 
of the primary endpoint was performed with no adjustment 
for opioid usage. The total postoperative opioid consumption 
through 72 hours was analyzed using a Wilcoxon rank-sum test. 
The proportion of subjects who were opioid free through 72 
hours was analyzed using Fisher’s exact test. All TEAEs were 
coded and tabulated by System Organ Class and Preferred Term.
resulTs
baseline characteristics
Of 438 subjects who were randomly assigned to the three study 
groups, 412 received one of the three interventions (ITT popu-
lation; figure 1). Baseline disease characteristics were similar 
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Figure 1 Consort flow diagram for EPOCH 1 study. HCl, hydrochloride; ITT, intent to treat; TEAE, treatment-emergent adverse event.











  Mean (SD) 47.3 (12.83) 45.5 (14.79) 48.0 (14.47)
  Min, max 19, 77 18, 77 18, 77
Sex, n (%)
  Female 86 (86.0) 132 (85.2) 138 (87.9)
  Male 14 (14.0) 23 (14.8) 19 (12.1)
Race, n (%)
  American Indian or Alaskan 
Native
0 2 (1.3) 1 (0.6)
  Asian 2 (2.0) 1 (0.6) 8 (5.1)
  Black or African descent 12 (12.0) 22 (14.2) 24 (15.3)
  Native Hawaiian or another 
Pacific Islander
0 1 (0.6) 0
  White 86 (86.0) 128 (82.6) 123 (78.3)
  Multiple 0 1 (0.6) 1 (0.6)
Ethnicity, n (%)
  Hispanic or Latino 32 (32.0) 49 (31.6) 47 (29.9)
  Not Hispanic or Latino 68 (68.0) 106 (68.4) 110 (70.1)
Body mass index (kg/m2)
  Mean (SD) 27.9 (5.05) 27.2 (4.38) 27.3 (4.79)
  Median 27.3 26.7 26.8
  Min, max 17.5, 38.4 17.3, 38.5 18.3, 38.6
*ITT population includes all subjects who were randomized and received study drug.
HCl, hydrochloride; ITT, intent to treat.
between groups and most of the subjects were female, as 
expected given the surgical procedure (table 1).3
efficacy findings: primary and secondary endpoints
HTX-011 demonstrated statistically significant as well as clin-
ically relevant benefit for the primary endpoint and all four 
key secondary endpoints (table 2). Compared with saline 
placebo and bupivacaine HCl, application of HTX-011 resulted 
in sustained pain reduction through 72 hours, significantly 
less opioid consumption and significantly more subjects who 
remained opioid free.
Subjects who received HTX-011 showed a reduction in mean 
pain intensity over 72 hours of 27% compared with saline 
placebo (323.3 vs 445.3; p<0.001; the primary endpoint) 
and 18% compared with bupivacaine HCl (323.3 vs 393.5; 
p<0.001; the first key secondary endpoint). Compared with 
saline placebo, mean NRS pain intensity scores were lower 
in the HTX-011 group at all timepoints through 72 hours. A 
prespecified sensitivity analysis with no adjustment of opioid 
use consistently showed significant pain reduction for HTX-011 
compared with bupivacaine HCl and saline placebo (p<0.01 for 
both comparisons), confirming the robustness of the results of 
the primary analysis. Over the course of 72 hours after treat-
ment, total opioid consumption was significantly reduced by 
37% in those who received HTX-011 when compared with 
saline placebo (p<0.001; the second key secondary endpoint) 
and by 25% vs those who received bupivacaine HCl (p=0.002; 
the fourth key secondary endpoint). Overall, 29% of subjects 
who received HTX-011 were opioid free after 72 hours, whereas 
11% of those who received bupivacaine HCl (p<0.001; the third 
key secondary endpoint) and 2% of those who received placebo 
(p<0.001) were opioid free (figure 2). In addition, a significantly 
greater proportion of subjects who received HTX-011 were able 
to go without any rescue medication, including acetaminophen. 
After 72 hours, those treated with HTX-011 remained opioid 
free at a significantly higher rate through day 10 and through 
day 28 compared with subjects who received saline placebo or 
bupivacaine HCl. Among the 45 HTX-011 subjects who were 
opioid free during the 72 hours after surgery, 41 (91.1%) stayed 
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AUC0-72 of the NRS pain intensity scores†
  Mean (SD) 445.3 (155.8) 393.5 (153.8) 323.3 (182.6)
  Primary endpoint: p value‡ versus saline placebo <0.0001
  Secondary endpoint: p value‡ versus bupivacaine HCl 0.0002
Opioid consumption through 72 hours (MME)
  Mean (SD) 30.06 (21.01) 25.09 (21.55) 18.80 (19.80)
  Median (min, max) 25.0 (0, 80.0) 17.5 (0, 92.5) 12.5 (0, 83.0)
  Secondary endpoint: p value§ versus saline placebo <0.0001
  Secondary endpoint: p value§ versus bupivacaine HCl 0.0022
Opioid free through 72 hours
  n (%) 2 (2.0) 17 (11.0) 45 (28.7)
  P value§ versus saline placebo <0.0001
  Secondary end point: p value¶ versus bupivacaine HCl 0.0001
Opioid free through 72 hours is defined as subjects who had total MME opioid dose=0 from 0–72 hours. All doses of opioid rescue medication are expressed as intravenous MME.
*ITT population includes all subjects who are randomized and receive study drug. This population was used as the primary analysis population for all efficacy endpoints.
†Analyzed using wWOCF.
‡P values reflect results of an analysis of variance with randomized treatment as the main effect.
§P values were obtained using the Wilcoxon rank-sum test.
¶P values from Fisher's exact test.
AUC0-72, area under the curve through 72 hours; HCl, hydrochloride; ITT, intent to treat; MME, morphine milligram equivalent; NRS, Numeric Rating Scale of the pain intensity score; wWOCF, 
windowed worst observation carried forward.
Figure 2 Proportion of subjects experiencing severe pain at any time from 0 to 72 hours and proportion of subjects opioid free through 72 hours 
(ITT population). HCl, hydrochloride; ITT, intent to treat.
A separation in mean pain curves through 72 hours was 
apparent between groups who received HTX-011, bupivacaine 
HCl and saline placebo (figure 3). Fewer subjects in the HTX-011 
group experienced severe pain (53.5%); this proportion was 
significantly lower compared with saline placebo (83.0%) and 
bupivacaine HCl (75.5%; p<0.001 for both comparisons) 
(figure 3).
Subjects who received bupivacaine HCl experienced signifi-
cantly lower pain in the first 12 and 24 hours after surgery 
(AUC0-12 and AUC0-24) compared with those who received saline 
placebo, but pain in those who received bupivacaine HCl was 
not significantly different from placebo beyond 24 hours as 
measured by AUC24-72 (table 3, figure 3).
By comparison, HTX-011 significantly reduced pain in the 
first 12 and 24 hours versus both saline placebo and bupivacaine 
HCl (AUC0-12 and AUC0-24; p<0.001 for both comparators), 
and this reduction was maintained beyond 24 hours through 
the full 72 hours period (AUC24-72; p<0.01 vs bupivacaine HCl; 
p<0.001 vs placebo).
safety
HTX-011 was well tolerated and exhibited a TEAE profile like 
that of saline placebo and bupivacaine HCl (table 4).
The two most common TEAEs in the HTX-011 group were 
nausea and dizziness. The incidence of nausea was numeri-
cally lower in the HTX-011 group compared with both the 
saline placebo and bupivacaine HCl group (37.6% vs 43.6% 
and 45.5%, respectively). There were no differences in serious 
adverse events between groups, no drug-related serious adverse 
events and no discontinuations due to drug-related adverse 
events in the HTX-011-treated subjects. One death of unknown 
cause occurred 17 days after a subject received bupivacaine 
HCl and was deemed unlikely related to study drug. There was 
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Figure 3 Mean (SE) NRS pain intensity scores using wWOCF (ITT 
population). HCl, hydrochloride; ITT, intent to treat; NRS, Numeric Rating 
Scale; wWOCF, windowed worst observation carried forward.












  Mean (SD) 37.55 (15.65) 24.26 (14.23) 20.68 (17.54)
  P value versus saline 
placebo
<0.0001 <0.0001




  Mean (SD) 67.97 (22.98) 50.37 (22.94) 38.54 (28.08)
  P value versus saline 
placebo
<0.0001 <0.0001




  Mean (SD) 155.75 (48.49) 131.36 (48.86) 98.65 (59.55)
  P value versus saline 
placebo
0.0004 <0.0001




  Mean (SD) 289.59 (115.64) 262.09 (117.25) 224.64 (131.28)
  P value versus saline 
placebo
0.0806 <0.0001




  Mean (SD) 445.34 (155.79) 393.45 (153.76) 323.29 (182.64)
  P value versus saline 
placebo
0.0151 <0.0001
  P value versus 
bupivacaine HCl
0.0002
*ITT population includes all subjects who are randomized and received study drug. 
Analyzed using windowed worst observation carried forward (wWOCF). P values 
reflect results of an analysis of variance with randomized treatment as the main 
effect.
AUCx-y, area under the curve from x to y hours; HCl, hydrochloride; ITT, intent to 
treat; NRS, Numeric Rating Scale.











Any TEAE 79 (78.2) 131 (85.1) 131 (83.4)
Severe TEAEs 3 (3.0) 7 (4.5) 5 (3.2)
SAEs 1 (1.0) 3 (1.9) 3 (1.9)
Deaths 0 1 (0.6) 0
Drug-related SAEs 0 0 0
TEAEs leading to study 
withdrawal
0 0 1 (0.6)
ORAEs† 54 (53.5) 78 (50.6) 69 (43.9)
Most common TEAEs 
(occurring in ≥15% of 
subjects in any group)
Nausea 44 (43.6) 70 (45.5) 59 (37.6)
Dizziness 18 (17.8) 36 (23.4) 34 (21.7)
Incision site edema 13 (12.9) 22 (14.3) 27 (17.2)
Vomiting 19 (18.8) 33 (21.4) 23 (14.6)
Adverse events were coded to preferred term using the Medical Dictionary for 
Regulatory Activities, version 19.1.
*Safety population includes all subjects who receive study drug, using actual 
treatment received.
†Subjects reporting more than 1 ORAE are counted only once.
ORAEs, opioid-related adverse events; SAE, serious adverse event; TEAE, treatment-
emergent adverse event.
no evidence of drug-related local anesthetic systemic toxicity 
(LAST) based on a comprehensive review of TEAEs, vital signs, 
ECGs and bupivacaine plasma concentrations (highest concen-
tration observed was 190 ng/mL). The proportion of subjects 
reported to have any wound-healing findings was similar across 
treatment groups. The most common wound-healing findings 
across all treatment groups were bruising, erythema and edema, 
with most resolving by the day 42 safety follow-up visit. There 
was no evidence of drug-related delayed bone healing based 
on X-rays through day 42 for all treatment groups. A lower 
proportion of subjects experienced ORAEs in the HTX-011 
group compared with the saline placebo and bupivacaine HCl 
groups (43.9% vs 53.5% and 50.6%, respectively). No clinically 
meaningful differences were observed between HTX-011, saline 
placebo and bupivacaine HCl for other tested safety parameters 
such as hematology and serum chemistry, vital signs and ECGs.
dIsCussIOn
In this phase III study, HTX-011 provided superior and sustained 
pain reduction compared with bupivacaine HCl through the crit-
ical 72 hours postoperative window, when pain is often most 
severe. HTX-011 is the only local anesthetic that has demon-
strated such efficacy in a phase III study. Significant reductions 
in pain occurred both early (in the first 24 hours) and were 
sustained from 24 hours to 72 hours. In addition to reductions in 
average pain scores, HTX-011 significantly reduced the propor-
tion of patients ever experiencing severe pain through 72 hours. 
The significant reductions in severe pain were consistent with 
the significant increase in opioid-free subjects over that period, 
and most subjects that required no opioids in the first 72 hours 
continued to be opioid free through 28 days.
Bupivacaine HCl solution administered by standard infiltra-
tion technique was chosen as the active comparator in this study 
because it accounts for approximately 70% of all local anes-
thetic usage in the USA (data on file). This study was powered 
to demonstrate head-to-head superiority of HTX-011 60 mg/1.8 
mg over bupivacaine HCl 50 mg using a statistically rigorous 
gated approach. The finding that bupivacaine HCl signifi-
cantly reduced pain in the first 12 and 24 hours versus placebo 
confirmed that the selected 50 mg dose was appropriate. The 
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study also confirmed that bupivacaine HCl does not produce 
significant pain reduction beyond 24 hours. Conversely, 
HTX-011 produced superior pain reduction versus bupivacaine 
HCl and placebo through the first 12 and 24 hours and beyond 
24 hours through 72. These results were shown to be robust 
when a prespecified sensitivity analyses without adjustment of 
opioid analgesic effect also showed superiority of HTX-011. 
This indicates that the statistical significance of the primary effi-
cacy outcome was not driven by the adjustment for opioid rescue 
medication use. When not adjusting pain scores for opioid rescue 
medication use, between-group differences remained significant, 
even though considerably more subjects in the saline placebo and 
bupivacaine HCl control groups than in the HTX-011 groups 
received opioid rescue medication and the total opioid consump-
tion was significantly higher in the control groups. This is the 
first time, to our knowledge, that an extended-release local anes-
thetic has shown significant analgesia versus either placebo or 
bupivacaine HCl beyond the first day after a single administra-
tion with or without adjustment for opioid use.
The 60 mg dose level for bupivacaine in HTX-011 was used 
based on prior phase II experience in bunionectomy.17 It is 
notable that approximately a third of the bupivacaine (22 mg) is 
released over the first 24 hours at this dose from the HTX-011 
and the very low dose of meloxicam in HTX-011 has been 
shown to produce no direct analgesic effect (data on file). There-
fore, the superiority of HTX-011 60 mg/1.8 mg (bupivacaine/
meloxicam) to bupivacaine HCl 50 mg is most likely because 
of synergy of the dual-acting components in HTX-011, as was 
previously observed in phase II studies.17
The clinical benefits of HTX-011 treatment included signifi-
cantly lowering the proportion of subjects who experienced 
severe pain, resulting in almost 30% more HTX-011-treated 
subjects not requiring any opioids during the 72-hour period 
compared with placebo. Consistent with fewer subjects taking any 
opioids, HTX-011-treated subjects experienced fewer ORAEs. 
Furthermore, among the HTX-011-treated subjects who were 
opioid free through 72 hours, more than 90% remained opioid 
free through day 10 and 82% remained opioid free through day 
28. These results may have further clinical relevance given that 
higher levels of opioid use in the acute postoperative period have 
consistently been found to predict chronic opioid use months 
after surgery.18–20
HTX-011 was well tolerated, with an AEs profile like that of 
saline placebo and bupivacaine HCl. Systemic toxicities with 
local anesthetics have been associated with high bupivacaine 
blood concentrations. In this study, there was no evidence of 
LAST with HTX-011. There was no evidence of delayed bone 
healing in this study, which included multiple assessments of 
bone healing and is consistent with several studies showing that 
short-term use of low-dose NSAIDs does not interfere with bone 
healing.21–23
This study has some limitations. Subjects were kept in-hos-
pital for 72 hours rather than discharged at 1–2 hours in order 
to ensure robust pain and pharmacokinetic data collection. 
Since there are no standard doses for bupivacaine HCl in bunio-
nectomy, the dose selected for the active control group was 
based on guidance from experienced surgeons and was within 
bupivacaine HCl labeling; statistically significant reductions in 
pain through 24 hours compared with placebo were observed 
for bupivacaine HCl, confirming the appropriateness of the 
selected dose. Although the current study focused on subjects 
undergoing bunionectomy, this is a well-established bony pain 
model,3 5 and therefore, the results may be generally applicable 
to other surgical procedures. Although this trial did not use 
scheduled multimodal analgesics (in order to assess the benefit 
of HTX-011 alone postoperatively for regulatory require-
ments), addition of non-opioid analgesics would be expected 
to further improve pain control and reduce opioid utilization. 
Future studies incorporating other non-opioid agents are neces-
sary to determine whether HTX-011 can serve as the keystone 
of non-opioid pain protocol for patients undergoing foot and 
ankle procedures.
In summary, the first 72 hours after surgery, when pain is 
the most severe, is also the most crucial for pain management 
and optimal patient recovery. Effective pain management and 
reduced exposure to opioids are associated with improved 
patient outcomes and reduced risk for ORAEs and the develop-
ment of chronic opioid use. HTX-011, a dual acting local anes-
thetic, is the first locally administered product to demonstrate 
superior, sustained pain reduction for 72 hours compared with 
both saline placebo and bupivacaine. Furthermore, the superior 
pain reduction with HTX-011 resulted in significantly fewer 
subjects experiencing severe pain, leading to reduced opioid 
consumption and a lower proportion of subjects who experi-
enced ORAEs. Importantly, a significantly higher proportion 
of subjects receiving HTX-011 had a completely opioid-free 
recovery following surgery. In light of the current need within 
the USA to reduce the amount of opioids prescribed to postsur-
gical patients, significant increases in the proportion of opioid-
free patients may enable physicians to write fewer of these 
prescriptions. HTX-011 was well tolerated with an AE profile 
similar to saline placebo and bupivicaine.
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